ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
IPO

Hong Kong biotech Prenetics tumbles after Nasdaq debut

CEO warns key COVID-19 testing business to drop as pandemic recedes

Prenetics Chief Executive Danny Yeung, right, stands with New World Development's Adrian Cheng during the biotech startup's trading debut on the Nasdaq on May 18. (Courtesy of Prenetics)
PAK YIU, Nikkei staff writer | Hong Kong

HONG KONG -- Biotech company Prenetics has lost more than one-third of its value since listing on the Nasdaq this week, as the Hong Kong startup's chief executive warned that a key virus-screening business was set for a steep fall.

Read Next

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close